Breakout Labs

NAPIGEN is a biotechnology company focused on innovative genome engineering across a variety of organisms, including plants, microbes, and animals. The company specializes in targeting organelles such as mitochondria and chloroplasts, which contain DNA essential for cellular energy production. By harnessing the capabilities of these organelles, NAPIGEN aims to enhance biological functions and contribute to advancements in agriculture, environmental sustainability, and other sectors, ultimately improving the quality of life in society.

Glyscend Therapeutics, established in 2014 and headquartered in Baltimore, Maryland, specializes in developing innovative treatments for metabolic diseases, with a primary focus on type 2 diabetes. The company's core product is a non-invasive, orally ingestible intestinal coating that mimics the positive effects of bariatric surgery, preventing the stimulation of duodenal mucosa and inhibiting key neurohormonal pathways in the proximal gut. This approach aims to provide patients with an effective, non-surgical strategy to manage their blood glucose levels, while also reducing potential side effects and offering healthcare providers a new tool to treat, rather than merely manage, the disease.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

NAPIGEN is a biotechnology company focused on innovative genome engineering across a variety of organisms, including plants, microbes, and animals. The company specializes in targeting organelles such as mitochondria and chloroplasts, which contain DNA essential for cellular energy production. By harnessing the capabilities of these organelles, NAPIGEN aims to enhance biological functions and contribute to advancements in agriculture, environmental sustainability, and other sectors, ultimately improving the quality of life in society.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Nuclease Probe Technologies specializes in developing rapid diagnostic assays that focus on phenotypic antibiotic susceptibility testing. The company’s innovative tests enable the detection of disease-associated nuclease activities and facilitate rapid pathogen identification directly from blood samples. This approach is particularly beneficial for patients suspected of having bloodstream infections, as it allows healthcare providers to quickly determine the most effective antibiotic for treatment. By providing early and accurate infection testing, Nuclease Probe Technologies aids veterinarians and physicians in making informed treatment decisions, ultimately improving patient outcomes and reducing unnecessary delays in care.

SciBac Inc. develops innovative live biotherapeutics aimed at treating antibiotic-resistant diseases while strengthening the microbiome. Founded in 2015 and located in Milpitas, California, the company utilizes a patented MERGE platform that employs directed evolution to enhance the efficacy of beneficial microorganisms. SciBac's initial therapeutics focus on chronic infections associated with cystic fibrosis, targeting pathogens such as Pseudomonas, Staphylococcus, Burkholderia, and non-tuberculous mycobacteria (NTM). By safely transferring beneficial genetic traits, SciBac's approach aims to promote rapid recovery and minimize the risk of reinfections, thereby improving treatment outcomes for patients facing these challenging infections.

Orion BioScience Inc. is a biotechnology company based in Omaha, Nebraska, founded in 2012. The company focuses on developing innovative solutions for autoimmune and antibody-mediated diseases through its Soluble Antigen Array (SAgA) platform. Orion BioScience specializes in the manufacture of pure drug particle agglomerates using its proprietary ORNx Formulation Technology, which facilitates the formulation of novel anti-inflammatory drugs in high concentration injectables. By addressing the challenges posed by autoimmune diseases and associated inflammation, Orion BioScience aims to offer therapeutic modalities that can significantly improve patient outcomes.

Pelitex Inc., established in 2015 and based in Syracuse, New York, specializes in the design and manufacturing of Nanogradient, a nanoparticle designed to mimic the properties of stainless steel. The company focuses on creating customizable nanoscale alloys that exhibit a range of critical properties, including magnetic, electrical, thermal, mechanical, and anti-corrosive characteristics. These materials are utilized in various sectors, such as life sciences, diagnostics, therapeutics, and drug discovery. Pelitex’s Nanogradient technology offers significant advantages over traditional materials like ferric oxide, particularly in terms of enhanced magnetism, stability, and conductivity. The company holds an intellectual property license to exploit this disruptive technology, positioning itself as a key player in the nanotechnology market. Pelitex aims to address complex challenges across multiple industries by providing innovative solutions that leverage the unique attributes of its advanced materials.

Phase Two Chemicals is a clean chemistry company focused on developing innovative technology for the on-site production of hydrogen peroxide. By utilizing an electrochemical catalyst research platform, the company aims to simplify the hydrogen peroxide production and delivery process. This technology enables clients, particularly in the pulp and paper mill industry, to produce cost-efficient electric chemicals. Through its advancements, Phase Two Chemicals seeks to enhance the efficiency and sustainability of hydrogen peroxide production.

CyteGen Corp., based in Shorewood, Wisconsin, operates a discovery platform focused on enhancing human health span by addressing age-related decline. The company explores new pathways that affect mitochondrial fitness and has shown potential in recovering cardiovascular and neurological functions through therapeutic interventions. Its platform has identified molecules that promote the removal of damaged mitochondria while facilitating the creation of new, healthy ones. This innovative approach enables healthcare professionals to integrate various data types, such as genomics, proteomics, and biochemical information, to enhance cellular metabolism and combat age-related diseases and suffering.

Phase Two Chemicals is a clean chemistry company focused on developing innovative technology for the on-site production of hydrogen peroxide. By utilizing an electrochemical catalyst research platform, the company aims to simplify the hydrogen peroxide production and delivery process. This technology enables clients, particularly in the pulp and paper mill industry, to produce cost-efficient electric chemicals. Through its advancements, Phase Two Chemicals seeks to enhance the efficiency and sustainability of hydrogen peroxide production.

UbiQD, LLC is a cleantech materials company based in Los Alamos, New Mexico, that specializes in the production of low-hazard quantum dots and nanocomposites. Founded in 2014, UbiQD aims to make its innovative materials widely accessible for various applications, including agriculture, safety, design, solar energy, lighting, security, and personal care. The company offers UbiGro, a retrofit luminescent film designed to enhance crop growth by optimizing sunlight in greenhouses. UbiQD's low-toxicity quantum dots are engineered to efficiently convert light from one color to another, making them suitable for a range of industries while adhering to safety standards. The firm's strategic location near Los Alamos and Sandia National Laboratory facilitates valuable collaborations with leading scientists, furthering its mission to advance nanomaterial production and application.

Ras Labs, LLC, founded in 2003 and based in Quincy, Massachusetts, specializes in the development and production of Synthetic Muscle, a polymer-based material that mimics natural movement by expanding and contracting in response to electrical impulses. This innovative technology is designed to enhance the interaction between mechanical devices and humans, with a focus on applications in prosthetics, rehabilitative robotics, and protective devices. In addition to Synthetic Muscle, Ras Labs creates robotic arm products that utilize material science advancements and data engineering to improve automation processes. These products include tactile sensors for robotic fingers, enabling gentle gripping of fragile objects and providing touch detection and location feedback, thus facilitating adaptable responses in automated gripping systems.

Blumio, Inc. is a San Francisco-based company founded in 2014 that specializes in developing non-invasive wearable sensors for cardiovascular diagnostics, particularly blood pressure monitoring. The company’s innovative technology employs radio frequency to detect and analyze arterial tissue movements, allowing for continuous blood pressure measurement without the need for traditional inflatable cuffs. Blumio aims to address the limitations of conventional blood pressure monitoring methods, which typically rely on measurements taken at rest with a sphygmomanometer. By providing a portable sensor that can be integrated with everyday devices, such as an iPhone case, Blumio enables users to accurately track their blood pressure throughout daily activities, enhancing the understanding of cardiovascular health.

C2Sense, Inc. specializes in developing chemiresistive gas sensors and miniaturized sensing technologies aimed at enhancing food quality and safety, particularly in the food and agriculture sectors. Founded in 2013 and based in Cambridge, Massachusetts, the company’s sensors detect gases like ethylene and biogenic amines at low concentrations, allowing stakeholders throughout the supply chain—from growers to consumers—to monitor the freshness of fruits, meats, and other perishable goods, ultimately reducing waste. C2Sense is also advancing its Halo Diagnostics product, a digitally connected immunoassay reader that offers near-PCR sensitivity and facilitates real-time test results through a cloud-based, HIPAA-compliant platform. This technology supports remote healthcare by enabling physicians to access patient test results instantly. Additionally, C2Sense has developed versatile sensing solutions that provide product quality information and counterfeit detection, using safe molecular additives that report on the status of goods throughout the distribution process, thereby enhancing security in various sectors, including pharmaceuticals and luxury goods.

CalWave focuses on developing innovative ocean wave technologies to provide reliable and cost-effective renewable energy solutions. Its proprietary wave energy converter operates fully submerged, ensuring high performance and durability in extreme weather conditions. By harnessing the energy of ocean waves, CalWave's technology converts this energy into electricity and freshwater. Given the consistent and predictable nature of wave power, it has the potential to meet 20-30% of global energy demand. CalWave aims to significantly reduce greenhouse gas emissions, targeting a displacement of 500 million tons annually by 2050. This technology could potentially power over 100 million homes in the United States, contributing to a more sustainable energy landscape.

Mat3ra is a company that offers a software platform aimed at enhancing the research and development of advanced materials and chemicals through materials modeling. By integrating high-fidelity simulations, large-scale data analytics, and machine learning, Mat3ra provides a hosted environment suitable for both public and private cloud deployments. This technology enables materials scientists to efficiently learn and utilize various physics-based artificial intelligence and machine learning modeling tools, facilitating the design and discovery of materials at the nanoscale.

Flightwave Aerospace Systems, based in Santa Monica, California, specializes in the development and manufacturing of long-range unmanned aerial vehicles (UAVs) and aerospace systems. Established in 2014, the company focuses on utilizing carbon-free energy sources to enhance the endurance and operational range of its vehicles, which range from small UAVs to advanced spacecraft. Flightwave's systems are designed for a variety of applications, including asset protection, environmental mapping, and wildlife monitoring. Their innovative thrust-vector control technology allows for seamless transitions between multi-rotor and fixed-wing flight, enabling aerial operations in diverse conditions without the need for pilot intervention.

Positron Dynamics, LLC is a technology company based in Port Angeles, Washington, founded in 2011 by Ryan Weed and Joshua Machacek. The company specializes in the development of advanced positron production and storage technologies. It offers semiconductor diagnostic tools designed to detect defects at the atomic level and focuses on applications such as non-destructive testing for aerospace and defense components. Positron Dynamics has developed innovative methods for generating and moderating cold positrons, which are also utilized in propulsion systems aimed at transforming spacecraft operations. The company's propulsion technology harnesses intense beams of cold positrons, potentially enabling the creation of efficient, anti-matter-powered spacecraft for deep space exploration. With several patents awarded for its pioneering technologies, Positron Dynamics is positioned at the forefront of research and development in the field of positron applications.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Seatrec is a climatetech startup focused on generating clean and sustainable energy from temperature differences in ocean waters. Founded in 2012 by Dr. Yi Chao, the company has leveraged technology developed at the NASA Jet Propulsion Laboratory to create patented thermal engine systems. These systems provide renewable electricity to power oceanographic research equipment such as drones, floats, and gliders. By utilizing Seatrec’s technology, researchers can significantly extend the operational life of their equipment, reduce costs, and enhance data collection capabilities, all while producing zero emissions and waste. The applications of this technology span various fields, including ocean data capture, seafloor mapping, offshore aquaculture, Arctic research, meteorology, and climate change mitigation.

ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. It specializes in the development of eco-friendly chemicals and bioprocesses using engineered microbes to convert renewable feedstocks, such as sugars, into industrial chemicals. The company’s bio-manufacturing platform aims to produce bio-based materials while minimizing carbon emissions during production, thereby supporting a carbon-efficient economy. By establishing cost-effective bioprocesses and novel biosynthetic pathways, ZymoChem enables clients to reduce production costs and enhance their competitiveness in the market. Through its innovative approach, the company contributes to sustainable manufacturing practices and the advancement of a real-zero economy.

C2Sense, Inc. specializes in developing chemiresistive gas sensors and miniaturized sensing technologies aimed at enhancing food quality and safety, particularly in the food and agriculture sectors. Founded in 2013 and based in Cambridge, Massachusetts, the company’s sensors detect gases like ethylene and biogenic amines at low concentrations, allowing stakeholders throughout the supply chain—from growers to consumers—to monitor the freshness of fruits, meats, and other perishable goods, ultimately reducing waste. C2Sense is also advancing its Halo Diagnostics product, a digitally connected immunoassay reader that offers near-PCR sensitivity and facilitates real-time test results through a cloud-based, HIPAA-compliant platform. This technology supports remote healthcare by enabling physicians to access patient test results instantly. Additionally, C2Sense has developed versatile sensing solutions that provide product quality information and counterfeit detection, using safe molecular additives that report on the status of goods throughout the distribution process, thereby enhancing security in various sectors, including pharmaceuticals and luxury goods.

Maxterial, Inc. is a company based in Richmond, California, founded in 2015, that specializes in the development of superhydrophobic materials to address issues such as corrosion, biofouling, and ice formation. By modifying the surface shape or texture of materials, Maxterial employs an advanced coating technology that mimics natural strategies, like the self-cleaning properties of the lotus leaf. This innovative approach significantly reduces the contact area of objects and droplets with the material's surface, enhancing its resistance to environmental effects. The company's method is affordable and easily integrated into existing manufacturing processes, offering safer and more environmentally friendly solutions for industries seeking effective corrosion prevention and wear resistance without the use of hazardous chemicals.

nanoGriptech, Inc. specializes in manufacturing micro-fibrillar polymer-based dry adhesives and surfaces, drawing inspiration from the natural adhesion mechanism of gecko feet. Founded in 2012 and headquartered in Pittsburgh, Pennsylvania, the company offers a range of products, including the Setex Gecko Tape, which is a repeatable, residue-free, non-tacky tape, and the Setex Ultra-Thin Fastener, designed for seamless integration with smooth surfaces. Its innovative adhesive solutions are tailored for diverse applications such as wearables, sports gear, semiconductors, robotics, medical devices, automotive components, and packaging. nanoGriptech aims to provide a superior alternative to traditional reusable adhesives, focusing on durability and customization. The company has established partnerships with multinational corporations and has recently begun small volume sales in the high-friction clothing market.

G-Tech Medical is focused on developing a wireless, wearable, and disposable electrode patch known as the GutCheck, which measures the electrical activity in the gastrointestinal tract, specifically the stomach, small intestine, and colon. This innovative device addresses a significant gap in diagnosing functional gastrointestinal disorders, such as abdominal pain, constipation, diarrhea, and bloating, which are often overlooked by traditional diagnostic methods like colonoscopies and CT scans. By monitoring myoelectrical signals over several days, the GutCheck patch provides physicians with valuable insights into gastrointestinal motility, enabling them to better tailor treatments for their patients. This non-invasive solution aims to improve clinical outcomes and reduce healthcare costs associated with gastrointestinal conditions.

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Modern Meadow, LLC is a biofabrication company based in Brooklyn, New York, founded in 2011. The company specializes in creating animal-free leather from living cells, utilizing its proprietary Bio-Alloy and Bio-Farm technology platforms. These innovations leverage tuned proteins to produce sustainable materials that eliminate the need for petrochemical and animal-derived inputs while maintaining high performance. Modern Meadow’s products are designed for seamless integration into existing infrastructures across various industries, including materials and beauty. The company emphasizes lab-to-brand traceability, ensuring that its offerings are fully transparent throughout the production process. By focusing on fermentation-based bio-collagen and lightweight materials, Modern Meadow aims to significantly reduce greenhouse gas emissions and promote sustainability without compromising quality or appearance.

C2Sense, Inc. specializes in developing chemiresistive gas sensors and miniaturized sensing technologies aimed at enhancing food quality and safety, particularly in the food and agriculture sectors. Founded in 2013 and based in Cambridge, Massachusetts, the company’s sensors detect gases like ethylene and biogenic amines at low concentrations, allowing stakeholders throughout the supply chain—from growers to consumers—to monitor the freshness of fruits, meats, and other perishable goods, ultimately reducing waste. C2Sense is also advancing its Halo Diagnostics product, a digitally connected immunoassay reader that offers near-PCR sensitivity and facilitates real-time test results through a cloud-based, HIPAA-compliant platform. This technology supports remote healthcare by enabling physicians to access patient test results instantly. Additionally, C2Sense has developed versatile sensing solutions that provide product quality information and counterfeit detection, using safe molecular additives that report on the status of goods throughout the distribution process, thereby enhancing security in various sectors, including pharmaceuticals and luxury goods.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules.

Siva Therapeutics Inc. is a biotechnology company focused on developing innovative nanotechnology solutions for cancer treatment. Founded in 2011 and based in Boulder, Colorado, the company specializes in creating SivaRods, a photothermal device that utilizes heat to irreversibly damage solid tumor tissues. By employing gold nanorods and an infrared light device, Siva Therapeutics offers a therapy that is more selective than traditional chemotherapy, less harmful than radiation, and avoids the risks associated with surgical interventions. The company's mission is to provide safe, minimally invasive, and cost-effective medical device treatments that enhance patient outcomes in the fight against cancer.

Siva Therapeutics Inc. is a biotechnology company focused on developing innovative nanotechnology solutions for cancer treatment. Founded in 2011 and based in Boulder, Colorado, the company specializes in creating SivaRods, a photothermal device that utilizes heat to irreversibly damage solid tumor tissues. By employing gold nanorods and an infrared light device, Siva Therapeutics offers a therapy that is more selective than traditional chemotherapy, less harmful than radiation, and avoids the risks associated with surgical interventions. The company's mission is to provide safe, minimally invasive, and cost-effective medical device treatments that enhance patient outcomes in the fight against cancer.

Longevity Biotech, Inc. is a biopharmaceutical company focused on developing innovative therapeutic drug candidates using its proprietary Hybridtide peptide technology. This platform enables the creation of customizable peptides that offer improved stability and absorption, enhancing treatment options for various medical conditions. The company's pipeline includes LBT-3627, a neuroprotective agent aimed at treating disorders such as Parkinson's disease; LBT-6030, a dual agonist targeting glucagon for metabolic conditions; and LBT-5001, a fusion inhibitor. Additionally, Longevity Biotech is conducting clinical studies to identify specific immune and inflammatory markers for the diagnosis of Parkinson's disease. Founded in 2010 and based in Philadelphia, Pennsylvania, Longevity Biotech is committed to advancing drug discovery and development in the biopharmaceutical sector.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.